Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

1. Management of Type 2 Diabetes Mellitus

Management of Type 2 Diabetes Mellitus Quality Department Guidelines for Clinical Care Ambulatory Diabetes Mellitus Guideline Team Team Leaders Connie J Standiford, MD General Internal Medicine Sandeep Vijan, MD General Internal Medicine Team Members Hae Mi Choe, PharmD College of Pharmacy R Van Harrison, PhD Medical Education Caroline R Richardson, MD Family Medicine Jennifer A Wyckoff, MD Metabolism, Endocrinology & Diabetes Consultants Martha M Funnell, MS, RN, CDE Diabetes Research (...) proper methods of care or excluding other acceptable methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding any specific clinical procedure or treatment must be made by the physician in light of the circumstances presented by the patient. Management of Type 2 Diabetes Mellitus Patient population. Adults Objectives. To reduce morbidity and mortality by improving adherence to important recommendations for preventing, detecting, and managing diabetic

2020 University of Michigan Health System

2. Comprehensive Type 2 Diabetes Management Algorithm - EXECUTIVE SUMMARY

Comprehensive Type 2 Diabetes Management Algorithm - EXECUTIVE SUMMARY Comprehensive Type 2 Diabetes Management Algorithm (2020) - EXECUTIVE SUMMARY | American Association of Clinical Endocrinologists search Search Resources BACK Offering Guidance Through the Latest Science on Bone-Related Disorders Treat your diabetes patients with expert precision. Offering Guidance Through the Latest Science on Lipid Conditions Education Menu FEATURED EMBR AACE 2020 EMBR AACE , the AACE 29 th Annual (...) to enhancing our members’ knowledge, education, and practice management skills so they can focus on providing the highest quality of patient care. We also advocate for the profession to create understanding of the value of our community to patients, organizations and the public. search Breadcrumb Comprehensive Type 2 Diabetes Management Algorithm (2020) - EXECUTIVE SUMMARY Footer Navigation Partner With Us Join us to develop an open dialogue between industry and foster AACE in the furtherance of patient

2020 American Association of Clinical Endocrinologists

3. Sotagliflozin with insulin for treating type 1 diabetes

an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Sotagliflozin with insulin for treating type 1 diabetes (TA622) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 21Contents Contents 1 Recommendations 4 2 Information about sotagliflozin 6 3 Committee discussion 7 Clinical management 7 Experience of people (...) -and- conditions#notice-of-rights). Page 3 of 211 1 Recommendations Recommendations 1.1 Sotagliflozin with insulin is recommended as an option for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m 2 , when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy, only if: sotagliflozin is given as one 200 mg tablet daily they are on insulin doses of 0.5 units/kg of body weight/day or more and they have completed a structured education programme

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

4. GLP-1 receptor agonists and stroke outcomes among patients with type 2 diabetes: a systematic review and meta-analysis

GLP-1 receptor agonists and stroke outcomes among patients with type 2 diabetes: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any (...) : Exclusion criteria: Example: Screening will be performed in two phases, namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2

2020 PROSPERO

5. Genetic epidemiology in susceptibility to type 2 diabetes mellitus in the Brazilian population: systematic review

Genetic epidemiology in susceptibility to type 2 diabetes mellitus in the Brazilian population: systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated (...) criteria: Example: Screening will be performed in two phases, namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal

2020 PROSPERO

6. Screening strategies for type 2 diabetes mellitus: a systematic review protocol

Screening strategies for type 2 diabetes mellitus: a systematic review protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email (...) will be performed in two phases, namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary

2020 PROSPERO

7. Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin and Suboptimal HbA1c in Andalusia (Spain): PLATEDIAN Study

collection Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions , 43 (2), 337-342 Feb 2020 Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin (...) , Sanofi Spain, Barcelona, Spain. PMID: 31831473 DOI: Item in Clipboard Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin and Suboptimal HbA 1c in Andalusia (Spain): PLATEDIAN Study Maria S Ruiz de Adana et al. Diabetes Care . Feb 2020 Show details Diabetes Care Actions , 43 (2), 337-342 Authors , , , , , , , , , , , , Affiliations 1 Endocrinology and Nutrition Department, Hospital Regional Universitario de Málaga, Málaga, Spain

2020 EvidenceUpdates

8. Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial Full Text available with Trip Pro

Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial Efficacy and Safety of Empagliflozin as Add-On to Insulin in Japanese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard (...) collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Obes Metab Actions 2019 Nov 6 [Online ahead of print] Efficacy and Safety of Empagliflozin as Add-On to Insulin in Japanese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial

2020 EvidenceUpdates

9. Impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal and mortality outcomes in people with Type 2 diabetes and proteinuria

Impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal and mortality outcomes in people with Type 2 diabetes and proteinuria Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Renal and Mortality Outcomes in People With Type 2 Diabetes and Proteinuria - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go (...) your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Review Diabet Med Actions , 37 (1), 44-52 Jan 2020 Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Renal and Mortality Outcomes in People With Type 2 Diabetes and Proteinuria

2020 EvidenceUpdates

10. Long-term Effects of Intensive Multifactorial Therapy in Individuals With Screen-Detected Type 2 Diabetes in Primary Care: 10-year Follow-Up of the ADDITION-Europe Cluster-Randomised Trial

Long-term Effects of Intensive Multifactorial Therapy in Individuals With Screen-Detected Type 2 Diabetes in Primary Care: 10-year Follow-Up of the ADDITION-Europe Cluster-Randomised Trial Long-term Effects of Intensive Multifactorial Therapy in Individuals With Screen-Detected Type 2 Diabetes in Primary Care: 10-year Follow-Up of the ADDITION-Europe Cluster-Randomised Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features (...) Create a new collection Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Lancet Diabetes Endocrinol Actions , 7 (12), 925-937 Dec 2019 Long-term Effects of Intensive Multifactorial Therapy in Individuals With Screen-Detected Type 2

2020 EvidenceUpdates

11. A 12-week, randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes

A 12-week, randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes A 12-week, Randomized, Double-Blind, Placebo-Controlled, Four-Arm Dose-Finding Phase 2 Study Evaluating Bexagliflozin as Monotherapy for Adults With Type 2 Diabetes - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go (...) your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Obes Metab Actions 2019 Nov 20 [Online ahead of print] A 12-week, Randomized, Double-Blind, Placebo-Controlled, Four-Arm Dose-Finding Phase 2 Study Evaluating Bexagliflozin as Monotherapy for Adults With Type 2

2020 EvidenceUpdates

12. Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications

Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications Prescrire IN ENGLISH - Spotlight ''Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications'', 1 January 2020 {1} {1} {1} | | > > > Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |  (...)  |   |  Spotlight In the January issue of Prescrire International - Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications FREE DOWNLOAD In the "Reviews" section this month: what is dapagliflozin's harm-benefit balance in type 2 diabetes, in light of the results of a recent randomised, double-blind trial studying the drug's effect on cardiovascular outcomes? Full text available for free download. Summary A randomised, double-blind trial of dapagliflozin

2020 Prescrire

13. Oral Semaglutide for Type 2 Diabetes: Effectiveness and Value

Oral Semaglutide for Type 2 Diabetes: Effectiveness and Value ©Institute for Clinical and Economic Review, 2019 Oral Semaglutide for Type 2 Diabetes: Effectiveness and Value Final Evidence Report December 9, 2019 Prepared for ©Institute for Clinical and Economic Review, 2019 Page i Final Evidence Report – Oral Semaglutide for Type 2 Diabetes Return to Table of Contents ICER Staff and Consultants University of Washington School of Pharmacy Modeling Group David M. Rind, MD, MSc Chief Medical (...) of Washington Ryan N. Hansen, PharmD, PhD Assistant Professor The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Department of Pharmacy University of Washington None of the above authors disclosed any conflicts of interest. DATE OF PUBLICATION: December 9, 2019 How to cite this document: Rind D, Guzauskas G, Fazioli K, Hansen R, Kumar V, Chapman R, Borrelli E, Bradt P, Pearson S. Oral Semaglutide for Type 2 Diabetes: Effectiveness and Value. Institute for Clinical and Economic Review

2020 California Technology Assessment Forum

14. Zingiber officinale (Ginger) for type 2 diabetes mellitus. A systematic review and meta-analysis

Zingiber officinale (Ginger) for type 2 diabetes mellitus. A systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external (...) : Screening will be performed in two phases, namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3

2020 PROSPERO

15. Systematic review of non-pharmacological interventions targeting type 2 diabetes mellitus and mental health co-morbidity in adults with severe mental illness

Systematic review of non-pharmacological interventions targeting type 2 diabetes mellitus and mental health co-morbidity in adults with severe mental illness Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content (...) : Inclusion criteria: Exclusion criteria: Example: Screening will be performed in two phases, namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review

2020 PROSPERO

16. The effectiveness of mobile phone messaging-based interventions to promote physical activity in type 2 diabetes: a systematic review

The effectiveness of mobile phone messaging-based interventions to promote physical activity in type 2 diabetes: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record (...) criteria: Exclusion criteria: Example: Screening will be performed in two phases, namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2

2020 PROSPERO

17. Vascular and metabolic effects of metformin added to insulin therapy in patients with type 1 diabetes: a systematic review and meta-analysis

Vascular and metabolic effects of metformin added to insulin therapy in patients with type 1 diabetes: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration (...) criteria: Exclusion criteria: Example: Screening will be performed in two phases, namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2

2020 PROSPERO

18. Comparing effects of continuous glucose monitoring systems (CGMs) and self-monitoring of blood glucose (SMBG) among adults with type 2 diabetes mellitus: a systematic review

Comparing effects of continuous glucose monitoring systems (CGMs) and self-monitoring of blood glucose (SMBG) among adults with type 2 diabetes mellitus: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability (...) : Exclusion criteria: Inclusion criteria: Exclusion criteria: Example: Screening will be performed in two phases, namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper

2020 PROSPERO

19. Comparative effect of glucose lowering drugs use on exercise capacity and muscle mass in patients with type 2 diabetes: a network meta-analysis

Comparative effect of glucose lowering drugs use on exercise capacity and muscle mass in patients with type 2 diabetes: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content (...) : Inclusion criteria: Exclusion criteria: Example: Screening will be performed in two phases, namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review

2020 PROSPERO

20. Effects of glycemic control on functional capacity in people with type 1 diabetes: a systematic review

Effects of glycemic control on functional capacity in people with type 1 diabetes: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files (...) : Example: Screening will be performed in two phases, namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3

2020 PROSPERO